Novo Nordisk’s patent expiration for its GLP-1 weight-loss drugs has sparked a significant shift in the Indian pharmaceutical market, with five domestic manufacturers launching generic versions at prices up to 80% lower than the original. Sun Pharmaceutical and Dr. Reddy’s Laboratories are leading this charge, offering semaglutide for as low as 750 rupees per weekly injection, compared to Novo’s pricing of 8,800 to 10,000 rupees. This development is crucial in a country where approximately 100 million people suffer from diabetes and a quarter are classified as obese.
The entry of generics is expected to impact Novo’s revenue, particularly as the company has already warned of potential sales declines in the coming years. While Novo has historically maintained a strong market position despite patent expirations, the aggressive pricing strategies of Indian firms could challenge its dominance. Analysts suggest that Novo may need to further reduce prices to retain market share in India, where the demand for GLP-1 drugs is rapidly increasing.
Market professionals should closely monitor how Novo responds to this competitive landscape. The ability to maintain a premium pricing strategy while ensuring accessibility will be key to its ongoing success in India, especially as more generics enter the market.
Source: cnbc.com